



John C. Lechleiter, Ph.D.

President and Chief Executive Officer

Eli Lilly and Company
Lilly Corporate Center
Indianapolis, Indiana 46285 U.S.A.
Phone 317 276 6997 Fax 317 276 0679

E-Mail jlechleiter@lilly.com

May 12, 2008

The Honorable Charles Grassley
U.S. Senate
135 Hart Senate Office Building
Washington, DC 20510

Dear Senator Grassley:

Eli Lilly and Company is pleased to announce our support of the revised Physicians Payments Sunshine Act, which will establish a national registry of payments to physicians by medical device, medical supply, and pharmaceutical companies.

Lilly embraces greater transparency in the health care system and believes this legislation represents an important step in building public trust in and understanding of the relationships between the pharmaceutical and device industries and physicians. This legislation will establish uniform reporting standards and help ensure that the public is informed about payments to physicians by companies seeking to increase physician knowledge about their products and thus improve patient care.

We are proud of our relationships with physicians who work with us in many important capacities, including clinical trials. We believe these physicians' efforts are vital to increasing the knowledge of their colleagues and advancing the science related to medicines, which will result in improving the treatment of current and future patients.

As you know, Lilly became the first company to voluntarily make public its clinical trials and clinical trials data in 2004; that information can be found at www.lillytrials.com. Last year, Lilly added another first by publicly reporting all of its educational grants and charitable contributions and, each quarter, posting the data online at www.lillygrantoffice.com. We are pleased to continue our industry leadership as your revised legislation moves through the process.

Best regards,

Answers That Matter.